How challenges related to diagnostic testing are jeopardizing patients and your ROI

Getting a drug to market is no easy task. It takes years of hard work and financial investment. But the job doesn’t end with a long-awaited FDA approval. If your drug is a targeted treatment, you have the added task of developing and commercializing a test to identify the right patients for your treatment. This typically requires a partnership with a companion diagnostics (CDx) developer. But the job does not end there. Indeed, just getting a targeted therapy and CDx on the market does not ensure that your targeted treatment will ultimately reach all the patients who could benefit. In reality, more than 150,000 patients are missed each year because of issues related to slow test turnaround times, poor sample management and inconsistent test results.1 For the pharma industry market, this translates into more than $16B in permanently lost revenue, which may be surprising. 1

How could so many patients be missing out on the promising opportunity of receiving targeted treatment? What is driving this monumental loss in revenue? Issues result from common hurdles in CDx development and commercialization that you might not even be aware of. Some of these testing hurdles include:

  • Tests not being adoptable by labs because of high cost or unavailability of a particular technology or testing platform
  • CDx kit manufacturers not adequately developing the market effectively, thereby limiting test uptake and utilization
  • Unestablished clinical utility of tests, resulting in lower reimbursement and limited access to important diagnostic tests
  • Low physician awareness of tests
  • Lack of investment in education about new tests from the test manufacturers and their pharma partners
  • Deliberate dismissal of the need for patient education on tests as the information is deemed too complicated to understand, limiting patient empowerment

Indeed, partnering with a CDx developer does not necessarily prepare you for any of these testing hurdles, obstructing the diagnostic development and commercialization landscape and, ultimately, preventing seamless test adoption. You may not realize it, but the typical CDx developer is not in the business of anticipating and circumventing these testing hurdles. Instead, you need the crucial additional help of an industry leader in data analytics and implementation services for diagnostic commercialization. This is where Diaceutics comes in.

Diaceutics works with pharmaceutical companies and its worldwide network of laboratories to help more patients get the right treatment at the right time through better, more efficient diagnostic testing. To do so, Diaceutics prepares and fortifies pharma with the following critical services:

  1. Diagnostic Landscape– Comprehensive analyses of the testing environment for pharmaceutical companies that identifies the risks and opportunities anticipated in the market, while providing essential, data-driven insights required to make decisions in advance of a launch.
  2. Planning – Advising on steps to ensure rapid and effective test adoption, including advice on how tests should be developed, who these tests should be developed with, and how they may be optimally communicated to physicians and patients.
  3. Implementation – Identifying and solving issues with leading laboratories relating to the adoption and efficacy of testing.
  4. Tracking – Ongoing post launch analysis to understand how tests are being utilized and if this is promoting or restricting access to a particular precision therapy.

Explore the following case studies demonstrating how Diaceutics has helped multiple pharma clients in their journeys from targeted therapy conception to test adoption and maximal patient reach.

  1. Case Study 1: Education, Raising Awareness and Reducing Test Turnaround Time Increases Number of Patients Treated with New Targeted Therapy
  2. Case Study 2: Insight into Testing Environment Drives Patient Acquisition/Reduces Patient Leakage
  3. Case Study 3: Increasing CDx Test Availability in Labs for New Lung Cancer Treatment Generates Additional US$200m in Revenue

1 FT US Healthcare & Life Sciences Summit, May 2017. “Transforming the pharma business model to prevent lost treatment opportunities and optimize return on investment” Keeling, P.

Webinars & Podcasts

Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases....
Liquid Biopsy in NSCLC
View all

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports


TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications